EUVIMEDEUVIMED entdecken
Crossref

Hepatic Sarcoidosis: Incidence, Presentation, and Treatment

L. Khayat, R. Jmai, E. Souilem

Endoscopy · 01.04.2024 · 56 (S 02 S 02) · S268

DOI: 10.1055/s-0044-1783323 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Endoscopy, erschienen am 01.04.2024. Verfasst von L. Khayat und 2 weiteren Autor:innen.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Sarcoidosis is a rare multi-systemic inflammatory disease of undetermined cause, characterized by the development of non-caseous granulomas affecting all organs. Liver damage is rare with a prevalence of 13%, and is most often asymptomatic. The aim of our study is to figure out the clinical, paraclinical and therapeutic characteristics of patients with hepatic sarcoidosis.

Methods

This is a retrospective descriptive study involving all patients followed for sarcoidosis between January 2015 and March 2023 at Monastir’s Internal Medicine Department.

Results

Among of 52 patients followed for systemic sarcoidosis, 17 patients had liver damage. The average age at the time of diagnosis was 44 years. Thirteen patients (76,47%) were female. The liver involvement was revealing of the disease in 06 cases. The circumstances of discovery were essentially hepatosplenomegaly in 10 cases (58.82%), hepatomegaly in 04 cases (23,52%), isolated splenomegaly within 1 case(5.8%), mucocutaneous jaundice and ascites in one case. The biological abnormalities found were anicteric cholestasis in 4 cases, icteric cholestasis in one case, hepatic cytolysis that predominates over ALT in 02 patients, and 02 cases of hepatocellular insufficiency were observed. The converting enzyme was elevated within 3 patients. The imaging showed a homogeneous hepatosplenomegaly in 09 cases, liver and splenic micronodules in 3 cases, heterogeneous hepatospenomegaly in 02 cases, isolated homogeneous splenomegaly in one case, a liver of chronic hepatopathy with signs of portal hypertension (expanded portal trunk, collateral venous circulation, ascites, homogeneous splenomenegaly) in 02 case. Histology exam confirmed the diagnosis within 04 patients showing granulomatous inflammation of liver tissue in 02 cases, chronic active hepatitis with portal and peri-portal fibrosis in 02 case. Among the extra-hepatic manifestations, an association with pulmonary (6 cases), ocular ( 04 cases) lymph nodes (04 cases), naso-sinuseous (02 cases)and skin (03) damages . All of our patients were given corticosteroid therapy at the dose of 0.5 mg/kg/day. The progression was marked by the regression of hepatomegaly with normalization of the liver balance in 58.8%, stabilization of the disease in 23.52% and progression to hepatocellular insufficiency and portal hypertension in 11.76%.

Conclusions

Our study shows that hepatic sarcoidosis is common with a prevalence of 32.69%, and hepatosplenomegaly is the most common way of detection. Treatment is mainly based on corticosteroids. The evolution to hepatocellular insufficiency and portal hypertension remains the most dreaded complications. Publication History Article published online: 15 April 2024 © 2024. European Society of Gastrointestinal Endoscopy. All rights reserved. Georg Thieme Verlag KG Rüdigerstraße 14, 70469 Stuttgart, Germany

Zitieren

APA

Khayat, L., Jmai, R., & Souilem, E. (2024). Hepatic Sarcoidosis: Incidence, Presentation, and Treatment. Endoscopy, 56(S 02 S 02), S268. https://doi.org/10.1055/s-0044-1783323

Vancouver

Khayat L, Jmai R, Souilem E. Hepatic Sarcoidosis: Incidence, Presentation, and Treatment. Endoscopy. 2024;56(S 02 S 02):S268. doi:10.1055/s-0044-1783323

BibTeX
@article{Khayat2024,
  author = {Khayat, L. and Jmai, R. and Souilem, E.},
  title = {Hepatic Sarcoidosis: Incidence, Presentation, and Treatment},
  journal = {Endoscopy},
  year = {2024},
  volume = {56},
  number = {S 02 S 02},
  pages = {S268},
  doi = {10.1055/s-0044-1783323}
}
Kostenlos starten →